[LI YAO, ZHANG GUO-BIAO, CHEN LEI, ZHANG XIAO-BO, HU GANG, GENG PENG-XIN, LI WEN-FEI, YAO HAO, HUANG SHI-LIN, ZHANG YA-MING, YAN LIN-JIE, TANG PING-MING, TANG YING-DE, ZHANG CHEN, YAN PANG-KE] CN Disclosed in the present invention are a heterocyclic compound as shown in formula (I) or a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt, or co-crystal thereof and a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating/preventing CCR4-mediated diseases. Groups in formula (I) are as defined in the description.

[LI YAO, ZHANG GUO-BIAO, ZHANG XIAO-PO, ZHANG YA-MING, YAN LIN-JIE, TANG PING-MING, YU YAN, ZHANG CHEN, YAN PANG-KE] CN Disclosed are a tricyclic fused heterocyclic compound having a PDE3/4 dual inhibitory effect represented by formula (I), a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating/preventing PDE3/4-mediated diseases. Each group in formula (I) is as defined in the description.

[LI YAO, CHEN LEI, ZHANG GUO-BIAO, WANG WEN-JING, SHI ZONG-JUN, HU GANG, HUANG HAI-TAO, WANG HAO-DONG, XU BO, ZHANG XIAO-BO, LIU GUO-LIANG, ZHENG DENG-YU, HUANG SHI-LIN, ZHAO JIAN-FEI, SONG CHANG-WEI, ZHANG CHEN, YE FEI, NI JIA, YAN PANG-KE] CN Provided are a compound of formula (I-a), an isomer thereof or a pharmaceutically acceptable salt thereof as a Hemagglutinin inhibitor, and a preparation method thereof. The compound is useful for preparing a medicament for treating a disease related to Hemagglutinin.

[LI YAO, SHI ZONG-JUN, ZHANG GUO-BIAO, CHEN LEI, WANG WEN-JING, ZHANG XIAO-BO, ZHENG DENG-YU, XU BO, LIU XIN, WANG YA-JUN, YE FEI, TANG PING-MING, NI JIA, ZHANG CHEN, YAN PANG-KE] CN Provided is a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a co-crystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a drug for treating obstructive airway diseases, bronchiectasis, cystic fibrosis, asthma, emphysema, chronic obstructive pulmonary diseases and other diseases.

[LI YAO, WANG WEN-JING, CHEN LEI, ZHANG GUO-BIAO, ZHANG XIAO-BO, HU GANG, WANG YA-JUN, WANG HAO-DONG, TANG PING-MING, YU YAN, ZHANG CHEN, YAN PANG-KE] CN Provided are a compound of formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic thereof, or a pharmaceutical composition comprising same, and use thereof as a ketohexokinase inhibitor in the preparation of drugs for treating related diseases. Each group in formula (I) is as defined in the description.

[LI YAO, WANG WEN-JING, ZHANG GUO-BIAO, SHI ZONG-JUN, CHEN LEI, ZHANG CHEN, YAN PANG-KE, ZHENG WEI] CN The present invention provides a preparation method for a fused tricyclic derivative and an intermediate. The fused tricyclic derivative has a structure represented by formula (I). In the preparation method, raw materials are easy to obtain, simple steps are comprised, and the preparation method is suitable for large-scale industrial production.

[LI YAO, SHI ZONG-JUN, ZHANG GUO-BIAO, WANG WEN-JING, CHEN LEI, PEI YUN-PENG, YANG LONG, SONG CHANG-WEI, TANG PING-MING, YE FEI, ZHANG CHEN, NI JIA, YAN PANG-KE] CN Disclosed are a compound of formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate, and an eutectic or deuterated compound thereof, or a pharmaceutical composition comprising same, and a use thereof as an EZH2 inhibitor in the preparation of a medication for treating related diseases. The definition of each group in formula (I) is consistent with that in the description.

[LI YAO, CHEN LEI, WANG WEN-JING, ZHANG GUO-BIAO, SHI ZONG-JUN, HUANG HAI-TAO, ZHAO JIAN-FEI, YANG LONG, LIU GUO-LIANG, HUANG SHI-LIN, TANG PING-MING, YE FEI, ZHANG CHEN, YAN PANG-KE] CN Provided are a compound of formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate and a eutectic crystal thereof, or a pharmaceutical composition containing same, and the use thereof as an EZH2 inhibitor in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description.

[LI YAO, SHI ZONG-JUN, ZHANG GUO-BIAO, WANG YONG-LI, YU YAN, ZHANG CHEN, YAN PANG-KE] CN Provided are a nitrogen-containing heterocyclic compound as represented by formula (I), or a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, an eutectic thereof or a pharmaceutical composition of them, and a use of the heterocyclic compound in preparation of a drug for treating/preventing diseases mediated by IL-17A. Groups in formula (I) are as defined in the description.

[LI YAO, SHI ZONG-JUN, ZHANG GUO-BIAO, PEI YUN-PENG, SHU TIAN-BO, WANG YAO-LING, WANG PENG-CHENG, ZHONG QI-JIE, LIU XIN, SHI SHAO-HUI, TANG PING-MING, ZHANG CHEN, YAN PANG-KE] CN A compound as represented by formula (I), or a stereoisomer, tautomer, deuterated compound, solvate, co-crystal or pharmaceutically acceptable salt of the compound and a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating/preventing CYP11A1-mediated diseases, wherein each group in formula (I) is as defined in the description.